TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6.
We examined the capacity of murine recombinant tumor necrosis factor (rmTNF) to induce an inhibitory effect at the hepatic stage on malaria induced by Plasmodium yoelii sporozoites. When injected three times, 1.0 micrograms of rmTNF was found to protect 78% of mice against a sporozoite challenge. In contrast, whatever the dose and the schedule of administration, no inhibition was observed when purified hepatocyte cultures were infected with P. yoelii. The addition of non-parenchymal hepatic cells to hepatocyte cultures restored the capacity of TNF to modulate hepatic stage development, leading to up to 44% inhibition. Antibodies to interleukin 6 reversed the anti-parasite activity in the co-culture system.
Nussler
A
A
INSERM U313, Groupe Pitié-Salpêtrière, Paris, France.
Pied
S
S
Goma
J
J
Rénia
L
L
Miltgen
F
F
Grau
G E
GE
Mazier
D
D
D000818:Animals; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000096:biosynthesis*; D008099:Liver / Q000276:immunology / Q000469:parasitology; D008288:Malaria / Q000276:immunology* / Q000469:parasitology; D051379:Mice; D008815:Mice, Inbred Strains; D010967:Plasmodium yoelii / Q000254:growth & development / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha